Ocugen (OCGN) Q3 2025 Earnings
How Did OCGN Stock React to Q3 2025 Earnings?
S&P 500 over the same 30 days: +0.89%.
Did OCGN Beat Earnings? Q3 2025 Results
No. Ocugen reported Q3 2025 earnings of $-0.07 a share on Nov 5, 2025, missing the $-0.06 consensus estimate by 21.7%. Revenue was $1.8M against a $440,000 estimate.
Ocugen delivered a mixed third quarter for fiscal 2025, posting a loss that widened beyond expectations even as revenue dramatically exceeded forecasts, painting a picture of a clinical-stage biotech burning cash to fuel an ambitious pipeline. The company earned $1.75 million in revenue, a 54.2% jump year-over-year that blew past the $440,000 consensus estimate by 298.18%, largely driven by the licensing deal with Kwangdong Pharmaceutical for OCU400 rights in South Korea. On the bottom line, however, Ocugen missed, reporting a loss of $0.07 per share against the $0.06 consensus estimate, a 21.74% shortfall, as operating expenses climbed to $19.38 million from $14.39 million a year ago on heavier R&D and clinical trial spending. The net loss widened to $20.05 million, leaving cash at $32.90 million with a runway extending only through Q2 2026, though warrant proceeds could push that into 2027. Looking ahead, the company is targeting a BLA rolling submission for OCU400 in H1 2026, with top-line Phase 3 data expected by Q4 2026, as management advances its goal of filing three BLAs over the next three years.
- Revenue growth from collaborative arrangement revenue related to Kwangdong licensing deal
- Increased R&D spending driven by advancing multiple late-stage clinical trials
- Higher G&A expenses supporting expanded operations
“With two late-stage modifier gene therapies on track to meet 2026 and 2027 BLA/MAA filings, it's remarkable to look back and recognize we only began dosing the first patient in the Phase 1/2 OCU400 clinical trial in 2022. The OCU410ST Phase 2/3 GARDian3 pivotal confirmatory trial is following close behind the OCU400 Phase 3 liMeLiGhT clinical trial, and with 50% enrollment completed to date, we believe recruitment will be completed in the first quarter of 2026. This progress not only reinforces our commitment to file three BLAs in the next three years, but it also brings us closer to addressing the incredible unmet medical needs that exist for patients facing vision loss.”
Ocugen CEO, on the earnings call
What Was Ocugen's Outlook in Q3 2025?
Ocugen expects current cash of $32.9 million to provide runway through Q2 2026, with an additional $30 million potential from warrant exercises that could extend runway into 2027. Key upcoming catalysts include: OCU410 Phase 2 full data release in Q1 2026, OCU410ST Phase 2/3 interim data (50% of patients at 8 months) mid-year 2026, OCU400 Phase 3 top-line data in Q4 2026, and initiation of BLA rolling submission for OCU400 in H1 2026. The company plans to initiate OCU410 Phase 3 in 2026 and targets a BLA filing for OCU410ST in H1 2027 and for OCU410 in 2028. The company will continue pursuing financing opportunities and strategic business development partnerships to fund operations through commercialization.
OCGN YoY Financials
| Metric | Q3 2025 | Q3 2024 | Year over year |
|---|---|---|---|
| Revenue | $1.8M | $1.1M | +54.2% |
| Operating Income | −$17.6M | −$26.3M | −33.0% |
| Net Income | −$20.1M | −$44.2M | −54.6% |
OCGN Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.